Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry

Journal of Experimental & Clinical Cancer Research

Xiaojun Zhou¹  Guangming Lu²  Kai Cheng¹  Xuan Wang¹  Bo Yu¹  Qunli Shi¹  Qin Shen¹  Jiandong Wang¹ 

[1] Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China;Department of Radiology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China

关键词: D5F3 clone;    IHC;    Lung squamous cell carcinoma;    Anaplastic lymphoma kinase;   

Others  :  1135995
DOI  :  10.1186/s13046-014-0109-2

 received in 2014-11-02, accepted in 2014-12-05,  发布年份 2014

【 摘 要 】

Background

The echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 5% of lung adenocarcimomas (ACA), leading to ALK overexpression and predicting response to targeted therapy. To the present, few studies have been focused on the expression of ALK protein in lung squamous cell carcinomas (SqCC). Only several cases of lung SqCC were reported expression of ALK protein. No clinical study has been published to explicit the relationship between ALK expression and the response to targeted therapy in SqCC.

Methods

In this study, we analyzed ALK protein expression with a specific rabbit monoclonal Ig antibody (D5F3 clone) in 207 cases of lung SqCC. The positive cases were confirmed with ALK fluorescence in situ hybridization (FISH) and RT-PCR.

Results

We found that 3 out of 207 (1.4%) cases of lung SqCC were ALK positive detected by IHC staining, which were confirmed by ALK FISH and RT-PCR.

Conclusions

Our results indicate that ALK protein expression is not a rare molecular event in SqCC. Although the frequency of EML4-ALK rearrangements is lower in lung SqCC than that in lung adenocarcinomas, their presence may provide additional treatment options in lung SqCC. The response of SqCC patients with ALK expression to target therapy of crizotinib should be explored.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kim C, Chapman RS, Hu W, He X, Hosgood HD, Liu LZ, Lai H, Chen W, Silverman DT, Vermeulen R, Tian L, Bassig B, Shen M, Zhang Y, Ma S, Rothman N, Lan Q: Smoky coal, tobacco smoking, and lung cancer risk in Xuanwei, China. Lung Cancer 2014, 84:31-35.
• [2]Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, Lindeman NI, Hornick JL: Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013, 8:322-328.
• [3]She J, Yang P, Hong Q, Bai C: Lung cancer in China: challenges and interventions. Chest 2013, 143:1117-1126.
• [4]Raaschou-Nielsen O, Andersen ZJ, Beelen R, Samoli E, Stafoggia M, Weinmayr G, Hoffmann B, Fischer P, Nieuwenhuijsen MJ, Brunekreef B, Xun WW, Katsouyanni K, Dimakopoulou K, Sommar J, Forsberg B, Modig L, Oudin A, Oftedal B, Schwarze PE, Nafstad P, De Faire U, Pedersen NL, Ostenson CG, Fratiglioni L, Penell J, Korek M, Pershagen G, Eriksen KT, Sørensen M, Tjønneland A, et al.: Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 2013, 14:813-822.
• [5]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [6]Shibata T, Kokubu A, Tsuta K, Hirohashi S: Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett 2009, 283:203-211.
• [7]Solomon B, Varella-Garcia M, Camidge DR: ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009, 4:1450-1454.
• [8]Lo FY, Tan YH, Cheng HC, Salgia R, Wang YC: An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer 2011, 117:5344-5350.
• [9]Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M: Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene 2013, 32:4034-4042.
• [10]Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP: Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. Exp Lung Res 2013, 39:328-335.
• [11]Douillard JY, Pirker R, O'Byrne KJ, Kerr KM, Storkel S, von Heydebreck A, Grote HJ, Celik I, Shepherd FA: Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J Thorac Oncol 2014, 9:717-724.
• [12]Waggott W, Lo YM, Bastard C, Gatter KC, Leroux D, Mason DY, Boultwood J, Wainscoat JS: Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma. Br J Haematol 1995, 89:905-907.
• [13]Pileri SA, Pulford K, Mori S, Mason DY, Sabattini E, Roncador G, Piccioli M, Ceccarelli C, Piccaluga PP, Santini D, Leone O, Stein H, Falini B: Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am J Pathol 1997, 150:1207-1211.
• [14]Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA: TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000, 157:377-384.
• [15]Gesk S, Gascoyne RD, Schnitzer B, Bakshi N, Janssen D, Klapper W, Martin-Subero JI, Parwaresch R, Siebert R: ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas. Leukemia 2005, 19:1839-1840.
• [16]Marino-Enriquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, Coffin CM, Hornick JL: Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol 2011, 35:135-144.
• [17]Yoshida A, Shibata T, Tsuta K, Watanabe S, Tsuda H: Inflammatory myofibroblastic tumour of the lung with a novel PPFIBP1-ALK fusion variant. Histopathology 2013, 63:881-883.
• [18]Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
• [19]Chiari R, Duranti S, Ludovini V, Bellezza G, Pireddu A, Minotti V, Bennati C, Crino L: Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. J Clin Oncol 2014, 32:e30-e32.
• [20]Pop O, Pirvu A, Toffart AC, Moro-Sibilot D: Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol 2012, 7:e1-e2.
• [21]Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011, 108:7535-7540.
• [22]Antoniu SA: Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693–703. Expert Opin Ther Targets 2011, 15:351-353.
• [23]Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH, Gandara DR: Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 2014, 9:18-25.
• [24]Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, Matsuo K, Mitsudomi T: Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012, 77:319-325.
• [25]Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC: EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 2012, 7:98-104.
• [26]Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K, Tsujimoto M: Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 2010, 63:1066-1070.
• [27]Yue D, Li H, Che J, Zhang Y, Tseng HH, Jin JQ, Luh TM, Giroux-Leprieur E, Mo M, Zheng Q, Shi H, Zhang H, Hao X, Wang C, Jablons DM, He B: Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res 2014, 33:34. BioMed Central Full Text
• [28]Abbruzzese C, Mattarocci S, Pizzuti L, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F, Amato R, D'Antona L, Rinaldi M, Felsani A, Perrotti N, Paggi MG: Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas. J Exp Clin Cancer Res 2012, 31:4. BioMed Central Full Text
• [29]Alrifai D, Popat S, Ahmed M, Gonzalez D, Nicholson AG, Parcq J, Benepal T: A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung Cancer 2013, 80:339-340.
• [30]Ochi N, Yamane H, Yamagishi T, Takigawa N, Monobe Y: Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene? Lung Cancer 2013, 79:94-95.
• [31]Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, et al.: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
• [32]Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, Liu HP, Chu Y, Chiu YT, Wu TH, Chou LH, Chen YR, Huang SF: Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One 2013, 8:e70839.
• [33]Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, Wright GM, Wainer Z, Horvath LG, Boyer M, McCaughan B, Kohonen-Corish MR, Fox S, Cooper WA, Solomon B: Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013, 26:1545-1553.
• [34]To KF, Tong JH, Yeung KS, Lung RW, Law PP, Chau SL, Kang W, Tong CY, Chow C, Chan AW, Leung LK, Mok TS: Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. J Thorac Oncol 2013, 8:883-891.
• [35]Dragnev KH, Gehr G, Memoli VA, Tafe LJ: ALK-rearranged adenosquamous lung cancer presenting as squamous cell carcinoma: a potential challenge to histologic type triaging of NSCLC biopsies for molecular studies. Clin Lung Cancer 2014, 15:e37-e40.